572 related articles for article (PubMed ID: 29641323)
1. Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice.
Shen S; Sanchez ME; Blomenkamp K; Corcoran EM; Marco E; Yudkoff CJ; Jiang H; Teckman JH; Bumcrot D; Albright CF
Hum Gene Ther; 2018 Aug; 29(8):861-873. PubMed ID: 29641323
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency.
Song CQ; Wang D; Jiang T; O'Connor K; Tang Q; Cai L; Li X; Weng Z; Yin H; Gao G; Mueller C; Flotte TR; Xue W
Hum Gene Ther; 2018 Aug; 29(8):853-860. PubMed ID: 29597895
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates α1-antitrypsin Deficiency Phenotype.
Bjursell M; Porritt MJ; Ericson E; Taheri-Ghahfarokhi A; Clausen M; Magnusson L; Admyre T; Nitsch R; Mayr L; Aasehaug L; Seeliger F; Maresca M; Bohlooly-Y M; Wiseman J
EBioMedicine; 2018 Mar; 29():104-111. PubMed ID: 29500128
[TBL] [Abstract][Full Text] [Related]
4. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency.
Borel F; Tang Q; Gernoux G; Greer C; Wang Z; Barzel A; Kay MA; Shultz LD; Greiner DL; Flotte TR; Brehm MA; Mueller C
Mol Ther; 2017 Nov; 25(11):2477-2489. PubMed ID: 29032169
[TBL] [Abstract][Full Text] [Related]
5. Advances in Alpha-1 Antitrypsin Gene Therapy.
Lorincz R; Curiel DT
Am J Respir Cell Mol Biol; 2020 Nov; 63(5):560-570. PubMed ID: 32668173
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1-antitrypsin.
Baligar P; Kochat V; Arindkar SK; Equbal Z; Mukherjee S; Patel S; Nagarajan P; Mohanty S; Teckman JH; Mukhopadhyay A
Hepatology; 2017 Apr; 65(4):1319-1335. PubMed ID: 28056498
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cytosine base editing and adenine base editing as a potential treatment for alpha-1 antitrypsin deficiency.
Packer MS; Chowdhary V; Lung G; Cheng LI; Aratyn-Schaus Y; Leboeuf D; Smith S; Shah A; Chen D; Zieger M; Cafferty BJ; Yan B; Ciaramella G; Gregoire FM; Mueller C
Mol Ther; 2022 Apr; 30(4):1396-1406. PubMed ID: 35121111
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.
Guo S; Booten SL; Aghajan M; Hung G; Zhao C; Blomenkamp K; Gattis D; Watt A; Freier SM; Teckman JH; McCaleb ML; Monia BP
J Clin Invest; 2014 Jan; 124(1):251-61. PubMed ID: 24355919
[TBL] [Abstract][Full Text] [Related]
9. In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA.
Cruz PE; Mueller C; Cossette TL; Golant A; Tang Q; Beattie SG; Brantly M; Campbell-Thompson M; Blomenkamp KS; Teckman JH; Flotte TR
Lab Invest; 2007 Sep; 87(9):893-902. PubMed ID: 17592477
[TBL] [Abstract][Full Text] [Related]
10. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.
Turner AM; Stolk J; Bals R; Lickliter JD; Hamilton J; Christianson DR; Given BD; Burdon JG; Loomba R; Stoller JK; Teckman JH
J Hepatol; 2018 Aug; 69(2):378-384. PubMed ID: 29572094
[TBL] [Abstract][Full Text] [Related]
11. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector.
Conlon TJ; Cossette T; Erger K; Choi YK; Clarke T; Scott-Jorgensen M; Song S; Campbell-Thompson M; Crawford J; Flotte TR
Mol Ther; 2005 Nov; 12(5):867-75. PubMed ID: 16085464
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin.
Sosulski ML; Stiles KM; Frenk EZ; Hart FM; Matsumura Y; De BP; Kaminsky SM; Crystal RG
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759494
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of Z Mutant Alpha-1 Antitrypsin In Vivo Using Modified DNA Antisense Oligonucleotides.
Aghajan M; Guo S; Monia BP
Methods Mol Biol; 2017; 1639():127-138. PubMed ID: 28752452
[TBL] [Abstract][Full Text] [Related]
14. Alpha-1-antitrypsin deficiency: from genoma to liver disease. PiZ mouse as model for the development of liver pathology in human.
Giovannoni I; Callea F; Stefanelli M; Mariani R; Santorelli FM; Francalanci P
Liver Int; 2015 Jan; 35(1):198-206. PubMed ID: 24529185
[TBL] [Abstract][Full Text] [Related]
15. Gene Delivery of Alpha-1-Antitrypsin Using Recombinant Adeno-Associated Virus (rAAV).
Song S; Lu Y
Methods Mol Biol; 2018; 1826():183-196. PubMed ID: 30194601
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for alpha-1 antitrypsin deficiency: an update.
Pires Ferreira D; Gruntman AM; Flotte TR
Expert Opin Biol Ther; 2023 Mar; 23(3):283-291. PubMed ID: 36825473
[TBL] [Abstract][Full Text] [Related]
17. Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency.
Karadagi A; Cavedon AG; Zemack H; Nowak G; Eybye ME; Zhu X; Guadagnin E; White RA; Rice LM; Frassetto AL; Strom S; Jorns C; Martini PGV; Ellis E
Sci Rep; 2020 Apr; 10(1):7052. PubMed ID: 32341402
[TBL] [Abstract][Full Text] [Related]
18. Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease.
Wooddell CI; Blomenkamp K; Peterson RM; Subbotin VM; Schwabe C; Hamilton J; Chu Q; Christianson DR; Hegge JO; Kolbe J; Hamilton HL; Branca-Afrazi MF; Given BD; Lewis DL; Gane E; Kanner SB; Teckman JH
JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32379724
[TBL] [Abstract][Full Text] [Related]
19. Adenine base editing reduces misfolded protein accumulation and toxicity in alpha-1 antitrypsin deficient patient iPSC-hepatocytes.
Werder RB; Kaserman JE; Packer MS; Lindstrom-Vautrin J; Villacorta-Martin C; Young LE; Aratyn-Schaus Y; Gregoire F; Wilson AA
Mol Ther; 2021 Nov; 29(11):3219-3229. PubMed ID: 34217893
[TBL] [Abstract][Full Text] [Related]
20. Heteropolymerization of α-1-antitrypsin mutants in cell models mimicking heterozygosity.
Laffranchi M; Berardelli R; Ronzoni R; Lomas DA; Fra A
Hum Mol Genet; 2018 May; 27(10):1785-1793. PubMed ID: 29538751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
